A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Ifinatamab deruxtecan (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYMAKER-U06 Substudy 06E
- Sponsors Merck Sharp & Dohme
- 24 Jan 2025 New trial record